FUS Ablation Feasible for Intermediate-Risk Prostate Cancer
In small phase II study, 93 percent free of clinically significant prostate cancer at treatment site at five-month biopsy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.